-transparent.png){kind=logo}
Amikacin was evaluated in patients with malignant diseases during 134 episodes of identified infection, most of which were cases of pneumonia and septicemia. The overall rate of response of the identified infections was 63%. The majority of infections were caused by Escherichia coli, the Klebsiella-Enterobacter-Serratia group, and Pseudomonas aeruginosa. The response rate for infections caused by these organisms was 80%. Five of eight infections caused by organisms resistant to gentamicin responded to therapy with amikacin. Nephrotoxicity was observed in 13% of patients who had normal renal function initially.
Related Publications
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
November 1981,
The Japanese journal of antibiotics,
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
January 1988,
Reviews of infectious diseases,
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
April 1972,
European journal of cancer,
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
November 2001,
Zhonghua nei ke za zhi,
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
January 1993,
Polski tygodnik lekarski (Warsaw, Poland : 1960),
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
June 1977,
The American journal of medicine,
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
March 1993,
The Japanese journal of antibiotics,
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
November 1976,
The Journal of infectious diseases,
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
January 1989,
La Clinica terapeutica,
G P Bodey, and
V Rodriguez, and
M Valdivieso, and
R Feld
October 1996,
Revue neurologique,
